Abstracts

572 – Optimized LNP-Induced Viral Outgrowth Assay to Quantify bNAb Sensitivity in the HIV Latent Reservoir

Background Broadly neutralizing antibodies (bNAbs) are currently being evaluated in clinical trials for HIV treatment and cure as immunomodulatory alternatives to standard antiretroviral therapy (ART). Existing methods are insufficient to accurately predict bNAb sensitivity of HIV-1 in vivo, especially for ART-treated individuals. In pursuit of a rapid, sensitive, and scalable pre-screening method, we report the…

1042 – Doxy-PEP Associated With Clearance of Mycoplasma genitalium Urogenital Infection

Background Mycoplasma genitalium (MG) causes 15-25% of nongonococcal urethritis cases in men. Antibiotic resistance limits treatment options. Doxycycline reduces bacterial load but is only 30-40% effective against MG, and is first in sequential treatment algorithms. Few studies have evaluated the impact of doxycycline post-exposure prophylaxis (doxy-PEP) on MG infection. Methods MG prevalence and incidence and clearance over…

325 – Evidence for Silent Mpox Transmission in Healthy Nigerian Adults

Background The 2022 multi-country mpox outbreak, driven by MPXV Clade IIb, spread to over 100 countries and highlighted uncertainties around the role of residual smallpox-derived immunity and silent transmission in shaping present-day susceptibility. In West Africa, where historical smallpox vaccination campaigns ended in 1980, large unvaccinated cohorts now coexist with older vaccinated individuals, yet the…

344 – Opioid Use Disorder Associates With Reduced HIV Reservoirs but Elevated Inflammation

Background Opioid use disorder (OUD) is highly prevalent among persons with HIV-1 (PWH). While opioids modulate the immune system, their impact on the HIV-1 reservoir during antiretroviral therapy (ART) remains unclear. We leveraged the OPIS cohort to compare reservoir features, immune milieu, and HIV-specific responses in ART-treated PWH with or without OUD. Methods We studied…

380 – HIV Reservoir Cells From ART‑Suppressed PWH Exhibit Distinct but Heterogeneous Glycomic Signatures

Background Glycans play essential roles in cell differentiation, homeostasis, and immunity. For example, sialylation enables cells to evade immune surveillance, while fucosylation is essential for T cell activation and clonal expansion. However, whether glycans are differentially expressed on HIV reservoir cells remains unknown. Here, we implement CyTOF-Lec to define glycan and protein features of reservoir…

1114 – HIV PrEP Product Preferences Among Clients Using Oral PrEP and PEP at Private Pharmacies in Kenya

Background Background: New long-acting injectable (LAI) HIV pre-exposure prophylaxis (PrEP) products require less frequent dosing and are more discreet than the daily oral standard. Their implementation in diverse settings, including private pharmacies, may help enhance PrEP reach and coverage. We assessed PrEP product preferences among clients obtaining daily oral PrEP or post-exposure prophylaxis (PEP) at…

671 – Soluble Glycoprotein 120 and Coronary Inflammation Measured by Pericoronary Fat Attenuation Index

Background People living with HIV (PWH) face an increased risk of cardiovascular disease (CVD) that cannot be fully explained by traditional risk factors. Viral antigens, such as the HIV-1 envelope subunit glycoprotein (gp120), have been shown to persist in plasma even when viral load is suppressed, and may directly contribute to vascular inflammation and CVD. The…

764 – Latent Tuberculosis Infection Is Strongly Associated With Increased Epigenetic Aging

Background Tuberculosis (TB) remains the deadliest infectious disease globally and is the primary cause of death among people with HIV. In 2023, an estimated 1.3 million individuals died from TB, and roughly one-fourth of the global population has been infected with latent TB (LTBI, asymptomatic M. tuberculosis infection). Epigenetics, which influences gene expression through mechanisms…

793 – Broadly Neutralizing Antibodies in Oral Secretion After Administration to Newborns Exposed to HIV

Background Broadly neutralizing antibodies (bNAbs) hold promise for HIV perinatal prophylaxis. Three anti-CD4 binding site bNAbs, VRC01, VRC01LS (longer plasma half-life), and VRC07-523LS (greater potency, longer plasma half-life), have favorable plasma pharmacokinetics (PK) when administered subcutaneously (SC) to newborns exposed to HIV. Concentrations of bNAbs in oral secretions (OS) may be relevant to protection from…